Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + naptumomab estafenatox
- Development stage
- Unknown
- Lead developer
- NeoTX Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
docetaxel + naptumomab estafenatox is a combination therapy under investigation for advanced or metastatic non-small cell lung cancer (NSCLC) and other solid tumors. **Docetaxel** is a well-established taxane chemotherapy that inhibits microtubule depolymerization, leading to cell cycle arrest and apoptosis. **Naptumomab estafenatox** is a recombinant fusion protein consisting of a mutated variant of the superantigen staphylococcal enterotoxin E (SEA/E-120) linked to the Fab fragment of an antibody targeting the tumor-associated antigen 5T4. This construct activates and expands specific T cells that recognize SEA/E-120, promoting their infiltration into tumors expressing 5T4[1][9][8]. The combination aims to enhance antitumor activity by combining direct cytotoxic effects with immune activation.
- Brand names
- Anyaradocetaxel
- Other names
- docetaxel + NAPdocetaxel + ABR-217620
02
Targets
TRBV (T-cell receptor beta variable chain family)MHC II (Major histocompatibility complex class II receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel + naptumomab estafenatox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + naptumomab estafenatox.